2024-515514-40-00招募中2 期
Prospective, randomized, neoadjuvant phase II study with combination immuno-oncology in primary clear cell renal cell cancer at risk for recurrence or distant metastases (NESCIO-trial; M21NSC; CA209-6DJ)
Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting1 个研究点 分布在 1 个国家目标入组 69 人开始时间: 2024年8月22日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 69
- 试验地点
- 1
- 主要终点
- Pathologic response rate, defined as the proportion of patients demonstrating a complete pathologic or partial pathologic response, according to central revision (pathology of NKI)
研究概览
简要总结
To investigate the rate of pathological responses following different neoadjuvant immunotherapy combinations in high-risk non-metastatic clear cell RCC in an adaptive trial design
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 否
入选标准
- •Adults at least 18 years of age
- •Women of childbearing potential must use appropriate method(s) of contraception. They should use an adequate method to avoid pregnancy for 23 weeks (30 days plus the time required for nivolumab to undergo five half-lives) after the last dose of investigational drug
- •Women of childbearing potential must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to the start of study treatment
- •Women who are not of childbearing potential (i.e., who are postmenopausal), or surgically sterile as well as azoospermic men do not require contraception
- •Patient is capable of understanding and complying with the protocol requirements and has signed the Informed Consent document.
- •World Health Organization (WHO) Performance Status 0 or 1
- •Histologically confirmed resectable clear cell RCC (measurable according to RECIST 1.1), that can be biopsied, and no history of distant metastases
- •Intermediate to high risk will be based on clinical TNM and biopsy nuclear grade. These are:
- •cT1b-cT2a grade 4 cN0 cM0
- •cT2b grade 3-4 cN0 cM0
- •cT3 any grade cN0 cM0
- •cT4 any grade cN0 cM0
- •cT any cN1 (fully resectable) cM0
- •No other malignancies, except adequately treated and a cancer-related life-expectancy of more than 5 years
- •Patient willing to undergo triple tumor biopsies and extra blood withdrawal during screening and in case of relapse
- •No prior immunotherapy targeting CTLA-4, PD-1 or PD-L1, or LAG-3
- •No immunosuppressive medications within 2 weeks prior start immunotherapy
- •Screening laboratory values must meet the following criteria: WBC ≥ 2.0x109/L, Neutrophils ≥1.5x109/L, Platelets ≥100 x109/L, Hemoglobin ≥5.5 mmol/L, Creatinine ≤1.5x ULN, AST ≤ 1.5 x ULN, ALT ≤ 1.5 x ULN, Bilirubin ≤1.5 X ULN, normal CK and Troponin T, normal LDH
排除标准
- •Distantly metastasized RCC
- •Allergies and Adverse Drug Reactions (like mastocytosis)
- •History of severe hypersensitivity reaction to any monoclonal antibody
- •Underlying medical conditions that, in the Investigator's opinion, will make the administration of study drug(s) hazardous or obscure the interpretation of toxicity or adverse events;
- •Pregnant or nursing
- •Concurrent medical condition requiring the use of immunosuppressive medications, or immunosuppressive doses of systemic or absorbable topical corticosteroids;
- •Use of other investigational drugs before study drug administration 30 days and 5 half-times before study inclusion
- •Relatlimab-specifik exclusion criteria: Participants with history of myocarditis, regardless of etiology.
- •Relatlimab-specifik exclusion criteria: Troponin T (TnT) > 2 × institutional ULN. Participants with TnT levels between > 1 to 2 × ULN will be permitted if a repeat levels within 24 hours are ≤ 1 ULN. If TnT levels are between >1 to 2 × ULN within 24 hours, the participant may undergo a cardiac consultation and be considered for treatment, following cardiologist recommendation. When repeat levels within 24 hours are not available, a repeat test should be conducted as soon as possible. If TnT repeat levels beyond 24 hours are < 2 × ULN, the participant may undergo a cardiac consultation and be considered for treatment, following cardiologist recommendation. Notification of the decision to enroll the participant following cardiologist recommendation has to be made to the BMS Medical Monitor or designee.
- •Relatlimab-specifik exclusion criteria:Left ventricular ejection fraction (LVEF) assessment with documented LVEF < 50% by either transthoracic echocardiogram (TTE) or multigated acquisition (MUGA) scan (TTE preferred test) within 6 months prior to start of study treatment.
- •Brain metastases (based on symptoms)
- •Non-clear cell RCC
- •No measurable lesion according to RECIST 1.1
- •Subjects with any active autoimmune disease or a documented history of autoimmune disease, or history of syndrome that required systemic steroids or immunosuppressive medications, except for subjects with vitiligo or resolved childhood asthma/atopy
- •Prior CTLA-4 or PD-1/PD-L1 or LAG-3 targeting immunotherapy
- •Radiotherapy prior or post-surgery
- •Patients will be excluded if they test positive for hepatitis B virus surface antigen (HBV sAg) or hepatitis C virus ribonucleic acid (HCV antibody), indicating acute or chronic infection; if treated and being at least one year free from HCV patients are allowed to participate
- •Patients will be excluded if they have known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS)
结局指标
主要结局
Pathologic response rate, defined as the proportion of patients demonstrating a complete pathologic or partial pathologic response, according to central revision (pathology of NKI)
Pathologic response rate, defined as the proportion of patients demonstrating a complete pathologic or partial pathologic response, according to central revision (pathology of NKI)
次要结局
- Safety, as measured by the frequency of immune-related adverse events leading to postponing of surgery for > 2 weeks
- Objective response rate, defined as the proportion of patients demonstrating a complete or partial response according to RECIST 1.1, at week 6
- Recurrence Free Survival (RFS), defined as the time from randomization to recurrence or death from any cause, whichever occurs first. Subjects last known to be alive, who have not experienced recurrence, will be censored
- Event-free survival (EFS), defined as the time from randomization to recurrence, distant metastasis, or death from any cause, whichever occurs first. Subjects who are event-free at the end of follow-up will be censored
- Rate of distant metastases, defined as the proportion of patients starting treatment who experience distant metastases during follow-up
- Rate of local recurrences, defined as the proportion of patients starting treatment who experience a local recurrence during follow-up
- Surgical morbidity following neoadjuvant immunotherapy (according Clavien Dindo classification)
研究者
Haanen
Scientific
Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
研究点 (1)
Loading locations...
相似试验
招募中
2 期
Phase II, multi‑cohort trial of neoadjuvant and post‑surgery IO102‑IO103 and pembrolizumab in patients with selected resectable tumors2022-502787-20-00IO Biotech ApS65
招募中
不适用
Response-adapted Total Neoadjuvant Therapy Guided by Induction Chemotherapy in Early- and Intermediate-risk Low Rectal Cancer for Implementation of a Watch-and-wait StrategyNCT07260526West China Hospital60
进行中（未招募）
1 期
Immunotherapy in neoadjuvant and adjuvant setting in patients with advanced HCC treated by electroporation in curative intent: French multicenter phase 2 therapeutic trial - NIVOLEPivolumab in neoadjuvant and adjuvant setting in patients with advanced HCC treated by electroporationMedDRA version: 20.0Level: PTClassification code 10073071Term: Hepatocellular carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-004679-29-FRASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)50
招募中
3 期
A Study Evaluating the Efficacy and Safety of Neoadjuvant Treatment with Atezolizumab or Placebo in Combination with Platinum-Based Chemotherapy in Patients with Resectable Stage II, IIIA, or Select IIIB Non-small cell lung cancer2023-504209-35-00F. Hoffmann-La Roche AG207
进行中（未招募）
不适用
a Neo-adjuvant Chemotherapy Immunotherapy in Resectable ESCC StudyThe Neoadjuvant Treatment for Resectable Esophageal Squamous Cell CarcinomaNCT06472635Zhejiang University95